Main links:
Home | About us | News and publications | Centre-led programmes | Funding schemes | Information portal

Site map | Help | Contact us | Media Centre | Accessibility | Disclaimer | Acknowledgements | Glossary



Welcome :: Home  :: News and publications :: News :: Challenging requirement for acute toxicity studies

News

Archived news

Challenging the requirement for acute toxicity studies – workshop report published

As part of a collaboration between the NC3Rs and the European pharmaceutical industry a working group of 15 international companies have been sharing and analysing the value of data from single dose rodent acute toxicity studies.

As part of a collaboration between the NC3Rs and the European pharmaceutical industry a working group of 15 international companies have been sharing and analysing the value of data from single dose rodent acute toxicity studies. The conclusion from this extensive review is that the information obtained from conventional acute toxicity studies is of little or no value in the pharmaceutical development process.

This scientifically driven approach has led to a challenge of the regulatory requirement for acute toxicity studies prior to first-in-man studies. To support discussions on the regulatory requirement for acute toxicity testing the NC3Rs held a workshop in London in November 2006 where the working group presented its findings to regulators from Japan, Europe and the US. Discussion at the workshop indicated that the recommendations of the working group are likely to be reflected in the new draft ICHM3 guidance. The work and the objectives of the group have the support of both EFPIA and PhRMA.

A report of the workshop is now available and it concludes that toxicity data are:




In this section:


Bookmark and Share
RSS Feed

Banners:


NC3Rs | 20 Park Crescent, London W1B 1AL | Tel: 020 7670 5331 | Fax: 020 7670 5178 | Email: enquiries@nc3rs.org.uk